

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

On: April 5, 2006

By: Ann Massey
Ann Massey

Attorney Docket No. 0169.410US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen *et al.*

Examiner: Ilia I. Ouspenski

Application No: 10/032,214

Art Unit: 1644

Filed: December 20, 2001

For: NOVEL CO-STIMULATORY
MOLECULES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Issue Fee


Sir:

The references cited on attached form PTO/SB/08A-B are being called to the attention of the Examiner. Copies of the non-US patent documents are provided. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

As this Information Disclosure Statement is being submitted before the mailing of the First Office Action, Applicants believe that no fee is due. However, in the event that a fee is due with this submission, the Commissioner is authorized to deduct any additional fees from, or credit any overpayment to, Deposit Account No. 50-0990.

Respectfully submitted,

By: 
Margaret A. Powers
Reg. No. 39,804

April 4, 2006
Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/032,214
	Filing Date	December 20, 2001
	First Named Inventor	Juha Punnonen, et al.
	Group Art Unit	1644
	Examiner Name	Ilia I. Ouspenski
	Attorney Docket Number	0169.410US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,861,310		Freeman et al.	01-19-1999	
	2	5,942,607		Freeman et al.	08-24-1999	
	3	6,071,716		Freeman et al.	06-06-2000	
	4	6,130,316		Freeman et al.	10-10-2000	
	5	6,653,444		Freeman et al.	11-25-2003	
	6	US 2003/0170821		Freeman et al.	09-11-2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T
	7	Azuma, M. et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," <i>Nature</i> 366:76-79 (1993)	
	8	Freeman, G.J. et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," <i>Science</i> 262:909-911 (1993)	
	9	Freeman, G.J. et al., "B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," <i>J. Immunol.</i> 143:2714-22 (1989)	
	10	Isono, T. & Seto, A., <i>Immunogenetics</i> 42:217-20 (1995)	
	11	Kim, J.J. et al., "Engineering DNA Vaccines Via Co-delivery of Co-Stimulatory Molecule Genes," <i>Vaccine</i> 16(19):1828-1835 (1998)	
	12	Lazetic, S. et al., "Chimeric Co-stimulatory Molecules that Selectively Act Through CD28 or CTLA-4 on Human T Cells," <i>J. Biol. Chem.</i> 277(41):38660-38668 (2002)	
	13	Parsons, K.R., et al., "Cloning of Cattle CD80," <i>Immunogenetics</i> 49(3):231-234 (1999)	
	14	Patten, P. et al., "Applications of DNA Shuffling to Pharmaceuticals and Vaccines," <i>Current Opinion in Biotechnology</i> 8:724-733 (1997)	
	15	Peach, R. et al., "Complementarity Determining Region 1 (CDR1)- and CDR3-Analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1," <i>J. Exp. Med.</i> 180:2049-2058 (1994)	
	16	Stamper, C. et al., "Crystal Structure of the B7-1/CTLA-4 Complex that Inhibits Human Immune Responses," <i>Nature</i> 410:608-611 (March 2001)	
	17	Stemmer, W. et al., "Searching Sequence Space: Using Recombination to Search More Efficiently and Thoroughly Instead of Making Bigger Combinatorial Libraries," <i>Biotechnology</i> 13:549-553 (1995)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.